Skip to main content
Heart logoLink to Heart
. 1999 Sep;82(3):333–335. doi: 10.1136/hrt.82.3.333

Safety of the transpulmonary ultrasound contrast agent NC100100: a clinical and haemodynamic evaluation in patients with suspected or proved coronary artery disease

Y Myreng 1, P Molstad 1, K Ytre-Arne 1, M Aas 1, L Stoksflod 1, J Nossen 1, B Oftedal 1
PMCID: PMC1729190  PMID: 10455084

Abstract

OBJECTIVE—To evaluate the clinical and haemodynamic safety of NC100100, a new transpulmonary ultrasound contrast agent intended for vascular use.
DESIGN—Pulmonary artery pressures and gas exchange, left ventricular and systemic blood pressure and ECG were measured at baseline, after saline injection, and after each of two increasing doses of NC100100 injected intravenously.
PATIENTS—30 patients who were evaluated for suspected coronary artery disease.
RESULTS—No change was detected in any of the haemodynamic variables, or in haematological or clinical chemical parameters. Blood gases were unchanged, as were heart rhythm and arterial oxygen saturation. No serious adverse reactions were reported.
CONCLUSIONS—NC100100 appeared to be haemodynamically inert and safe in patients with coronary artery disease.


Keywords: NC100100; ultrasound; safety

Full Text

The Full Text of this article is available as a PDF (61.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Feinstein S. B., Cheirif J., Ten Cate F. J., Silverman P. R., Heidenreich P. A., Dick C., Desir R. M., Armstrong W. F., Quinones M. A., Shah P. M. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. J Am Coll Cardiol. 1990 Aug;16(2):316–324. doi: 10.1016/0735-1097(90)90580-i. [DOI] [PubMed] [Google Scholar]
  2. Geny B., Mettauer B., Muan B., Bischoff P., Epailly E., Piquard F., Eisenmann B., Haberey P. Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients. J Am Coll Cardiol. 1993 Oct;22(4):1193–1198. doi: 10.1016/0735-1097(93)90437-6. [DOI] [PubMed] [Google Scholar]
  3. Munro H. M., Wood C. E., Taylor B. L., Smith G. B. Continuous invasive cardiac output monitoring--the Baxter/Edwards Critical-Care Swan Ganz IntelliCath and Viligance system. Clin Intensive Care. 1994;5(2):52–55. [PubMed] [Google Scholar]
  4. Ostensen J., Hede R., Myreng Y., Ege T., Holtz E. Intravenous injection of Albunex microspheres causes thromboxane mediated pulmonary hypertension in pigs, but not in monkeys or rabbits. Acta Physiol Scand. 1992 Mar;144(3):307–315. doi: 10.1111/j.1748-1716.1992.tb09299.x. [DOI] [PubMed] [Google Scholar]
  5. Rovai D., Monaghan M. J. New contrast agents and technologies for myocardial contrast echocardiography. Heart. 1997 Aug;78 (Suppl 1):7–11. doi: 10.1136/hrt.78.suppl_1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Skyba D. M., Camarano G., Goodman N. C., Price R. J., Skalak T. C., Kaul S. Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second-generation echocardiographic contrast agent capable of producing myocardial opacification from a venous injection. J Am Coll Cardiol. 1996 Nov 1;28(5):1292–1300. doi: 10.1016/S0735-1097(96)00328-2. [DOI] [PubMed] [Google Scholar]
  7. Yelderman M. Continuous measurement of cardiac output with the use of stochastic system identification techniques. J Clin Monit. 1990 Oct;6(4):322–332. doi: 10.1007/BF02842492. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES